Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial
Autor: | Christopher M. Walker, Christopher C. Phelps, Jonathan Honegger |
---|---|
Rok vydání: | 2021 |
Předmět: |
Viral Hepatitis Vaccines
0301 basic medicine Hepatitis C vaccine Hepatitis C virus T cells Review Hepacivirus medicine.disease_cause Microbiology Virus 03 medical and health sciences 0302 clinical medicine Viral Envelope Proteins Immunity vaccine Virology Animals Humans antibodies Medicine B cells business.industry Transmission (medicine) Immunogenicity Antibodies Monoclonal clinical trial Hepatitis C Antibodies chronic infection Vaccine efficacy Antibodies Neutralizing Hepatitis C immunity QR1-502 Clinical trial 030104 developmental biology Infectious Diseases Immunology 030211 gastroenterology & hepatology Hepatitis C Antigens business hepatitis C virus (HCV) |
Zdroj: | Viruses, Vol 13, Iss 1351, p 1351 (2021) Viruses |
ISSN: | 1999-4915 |
Popis: | Thirty years after its discovery, the hepatitis C virus (HCV) remains a leading cause of liver disease worldwide. Given that many countries continue to experience high rates of transmission despite the availability of potent antiviral therapies, an effective vaccine is seen as critical for the elimination of HCV. The recent failure of the first vaccine efficacy trial for the prevention of chronic HCV confirmed suspicions that this virus will be a challenging vaccine target. Here, we examine the published data from this first efficacy trial along with the earlier clinical and pre-clinical studies of the vaccine candidate and then discuss three key research directions expected to be important in ongoing and future HCV vaccine development. These include the following: 1. design of novel immunogens that generate immune responses to genetically diverse HCV genotypes and subtypes, 2. strategies to elicit broadly neutralizing antibodies against envelope glycoproteins in addition to cytotoxic and helper T cell responses, and 3. consideration of the unique immunological status of individuals most at risk for HCV infection, including those who inject drugs, in vaccine platform development and early immunogenicity trials. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |